下载App
扫码立即下载
  • 下载App

    扫码立即下载

  • 在线客服

    登录后咨询在线客服
+
恭喜您!
成功领取价值超 5000港元/年的高级行情
前往体验 >>

BetterLife Launches New Corporate Website
BetterLife推出新的公司网站

GlobeNewswire ·  {{timeTz}}

VANCOUVER, British Columbia, Feb. 10, 2022 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. ("BetterLife" or the "Company") (CSE: BETR/ OTCQB: BETRF/ FRA: NPAU), an emerging biotech company focused on the development and commercialization of 2nd-generation non-hallucinogenic psychedelic analogs for the treatment of neuropsychological disorders, is pleased to announce the launch of its new website. The Company's newly designed website better presents BetterLife's mission to develop new and innovative medicines to treat mental health disorders, such as depression and anxiety. The new website can be accessed at 

温哥华,不列颠哥伦比亚省,2022年2月10日(Global Newswire)--BetterLife Pharma Inc.(以下简称“BetterLife”或“公司”)(CSE:BETR/OTCQB:BETRF/FRA:NPAU),一家专注于2-甲氧基苯丙胺的开发和商业化的新兴生物技术公司(CSE:BETR/OTCQB:BETRF/FRA:NPAU)发送治疗神经心理障碍的新一代非致幻迷幻类似物公司很高兴地宣布推出其新网站。该公司最新设计的网站更好地体现了BetterLife开发治疗精神疾病(如抑郁症和焦虑症)的新型创新药物的使命。新网站可通过以下网址访问:

"In the past year, our team made significant advancements in development of our lead compounds, BETR-001 and BETR-002. We have obtained solid pre-clinical data to position BETR-001 as a leading candidate for potential treatment of certain mental health disorders affecting millions around the world. The non-hallucinogenic properties of BETR-001, combined with our proprietary non-controlled (scheduled) manufacturing process, allows for faster development and treatment of millions of additional patients. With recent guidance from the FDA, we continue to generate additional data to complete our Investigational New Drug (IND) Application to be submitted second half of this year," said BetterLife's Chief Executive Officer, Dr. Ahmad Doroudian.

在过去的一年里,我们的团队在开发我们的先导化合物BETR-001和BETR-002方面取得了重大进展。我们已经获得了坚实的临床前数据,将BETR-001定位为潜在治疗影响全球数百万人的某些精神健康疾病的领先候选药物。BETR-001的非致幻特性,与我们专有的非受控(计划)制造工艺相结合,可以更快地开发和治疗数百万额外的患者。在FDA最近的指导下,我们继续生成额外的数据,以完成我们将于今年下半年提交的研究新药(IND)申请。“BetterLife公司首席执行官艾哈迈德·多鲁迪安博士说。

About BetterLife Pharma

关于BetterLife Pharma

BetterLife Pharma Inc. is an emerging biotechnology company primarily focused on developing and commercializing two compounds, BETR-001 and BETR-002, to treat neuro-psychiatric and neurological disorders.

BetterLife制药公司是一家新兴的生物技术公司,主要致力于开发和商业化两种化合物BETR-001和BETR-002,用于治疗神经精神和神经疾病。

BETR-001 (formerly TD-0148A), which is in preclinical and IND-enabling studies, is a non-hallucinogenic and non-controlled LSD derivative in development and it is unique in that it is unregulated and therefore can be self-administered. BetterLife's synthesis patent for BETR-001 eliminates regulatory hurdles and its pending patent for composition and method of use covers treatment of depression, cluster headaches, post-traumatic stress disorder and other neuro-psychiatric and neurological disorders.

Betr-001(前身为TD-0148A)正在进行临床前和IND支持研究,是一种正在开发中的非致幻和非受控LSD衍生物,其独特之处在于它不受监管,因此可以自我给药。BetterLife用于BETR-001的合成专利消除了管理障碍,其正在申请的组合物和使用方法专利涵盖治疗抑郁症、丛集性头痛、创伤后应激障碍和其他神经精神和神经紊乱。

BETR-002 (formerly TD-010), which is in preclinical and IND-enabling studies, is based on honokiol, the active anxiolytic ingredient of magnolia bark. BetterLife's pending method of use and formulations patent covers treatment of anxiety related disorders including benzodiazepine dependency.

Betr-002(前身为TD-010)是基于厚朴树皮中的有效抗焦虑成分和厚朴酚,正在进行临床前和IND研究。BetterLife正在申请的使用方法和配方专利涵盖了治疗焦虑症相关疾病,包括对苯二氮类药物的依赖。

BetterLife also owns a drug candidate for the treatment of viral infections such as COVID-19 and is in the process of seeking strategic alternatives for further development.

BetterLife还拥有一种治疗新冠肺炎等病毒感染的候选药物,目前正在寻找进一步发展的战略替代药物。

For further information, please visit 

欲了解更多信息,请访问

Contact Information

联系信息

David Melles, Investor Relations Manager
Email: David.Melles@blifepharma.comPhone: 1-778-887-1928

大卫·梅尔斯投资者关系经理
电子邮件:David.Melle@blifepharma.com电话:1-778-887-1928

Cautionary Note Regarding Forward-Looking Statements

有关前瞻性陈述的注意事项

No securities exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.

没有任何证券交易所对本新闻稿内容的充分性或准确性进行审查或承担责任。本新闻稿包含与产品开发、许可、商业化和法规遵从性问题有关的前瞻性陈述,以及其他非历史事实的陈述。前瞻性陈述通常由诸如“将”、“可能”、“应该”、“预期”、“期望”和类似的表达方式来识别。本新闻稿中除历史事实陈述外的所有陈述均为前瞻性陈述,涉及风险和不确定因素。不能保证这些陈述将被证明是准确的,实际结果和未来事件可能与这些陈述中预期的大不相同。可能导致实际结果与本公司预期大相径庭的重要因素包括未能满足相关证券交易所的条件以及本公司不时提交给证券监管机构的文件中详细说明的其他风险。提醒读者,在准备任何前瞻性信息时使用的假设可能被证明是不正确的。由于许多已知和未知的风险、不确定性和其他因素,其中许多不是公司所能控制的,事件或情况可能导致实际结果与预测的结果大不相同。提醒读者不要过度依赖任何前瞻性信息。这些信息,尽管管理层在准备时认为是合理的, 可能被证明是不正确的,实际结果可能与预期的大不相同。本新闻稿中包含的前瞻性陈述明确受本警告性声明的限制。本新闻稿中包含的前瞻性陈述是截至本新闻稿发布之日作出的,公司将根据适用法律的明确要求,公开更新或修改任何包含的前瞻性陈述。


本页的译文内容由软件翻译。富途将竭力但却不能保证翻译内容之准确和可靠,亦不会承担因任何不准确或遗漏而引起的任何损失或损害。

风险提示:以上内容仅作为作者或者嘉宾的观点,不代表富途的任何立场,不构成与富途相关的任何投资建议。在作出任何投资决定前,投资者应根据自身情况考虑投资产品相关的风险因素,并于需要时咨询专业投资顾问意见。富途竭力但不能证实上述内容的真实性、准确性和原创性,对此富途不做任何保证和承诺。